EUVIMEDEUVIMED entdecken
Open Access

Alterations of pain pathways by experimental sleep disturbances in humans: central pain-inhibitory, cyclooxygenase, and endocannabinoid pathways

Monika Haack iD, Larissa C Engert iD, Luciana Besedovsky, Michael R Goldstein iD, Jaime K Devine iD, Rammy Dang iD, Keeyon Olia, Victoria Molina, Suzanne M Bertisch, Navil Sethna, Norah Simpson

SLEEP · 13.06.2023 · 46 (6)

DOI: 10.1093/sleep/zsad061 ↗

Kurz gefasst

Fachartikel in der Zeitschrift SLEEP, online erschienen am 07.03.2023. Verfasst von Monika Haack und 10 weiteren Autor:innen. Beteiligte Einrichtung: Harvard Medical School, Boston, MA, USA. Hauptthemen laut MEDLINE: Chronic Pain, Sleep Wake Disorders. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCRR NIH HHS, NINDS NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objectives There is strong evidence that sleep disturbances are an independent risk factor for the development of chronic pain conditions. The mechanisms underlying this association, however, are still not well understood. We examined the effect of experimental sleep disturbances (ESDs) on three pathways involved in pain initiation/resolution: (1) the central pain-inhibitory pathway, (2) the cyclooxygenase (COX) pathway, and (3) the endocannabinoid (eCB) pathway.

Methods

Twenty-four healthy participants (50% females) underwent two 19-day long in-laboratory protocols in randomized order: (1) an ESD protocol consisting of repeated nights of short and disrupted sleep with intermittent recovery sleep; and (2) a sleep control protocol consisting of nights with an 8-hour sleep opportunity. Pain inhibition (conditioned pain modulation, habituation to repeated pain), COX-2 expression at monocyte level (lipopolysaccharide [LPS]-stimulated and spontaneous), and eCBs (arachidonoylethanolamine, 2-arachidonoylglycerol, docosahexaenoylethanolamide [DHEA], eicosapentaenoylethanolamide, docosatetraenoylethanolamide) were measured every other day throughout the protocol.

Results

The central pain-inhibitory pathway was compromised by sleep disturbances in females, but not in males (p < 0.05 condition × sex effect). The COX-2 pathway (LPS-stimulated) was activated by sleep disturbances (p < 0.05 condition effect), and this effect was exclusively driven by males (p < 0.05 condition × sex effect). With respect to the eCB pathway, DHEA was higher (p < 0.05 condition effect) in the sleep disturbance compared to the control condition, without sex-differential effects on any eCBs.

Conclusions

These findings suggest that central pain-inhibitory and COX mechanisms through which sleep disturbances may contribute to chronic pain risk are sex specific, implicating the need for sex-differential therapeutic targets to effectively reduce chronic pain associated with sleep disturbances in both sexes. Clinical Trials Registration NCT02484742: Pain Sensitization and Habituation in a Model of Experimentally-induced Insomnia Symptoms. https://clinicaltrials.gov/ct2/show/NCT02484742.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chronic PainSleep Wake DisordersMaleFemaleHumansCyclooxygenase 2EndocannabinoidsLipopolysaccharidesSleepChronic DiseaseDehydroepiandrosterone

Stichwörter der Autor:innen

central pain modulationcyclooxygenaseendocannabinoidspain mechanismssex differencessleep disturbance

Substanzen

Cyclooxygenase 2EndocannabinoidsLipopolysaccharidesDehydroepiandrosterone

Autor:innen und Institutionen

  • Harvard Medical School, Boston, MA, USA.
  • Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA, USA.
  • Institute of Medical Psychology, Ludwig-Maximilians-Universität München, Munich, Germany.
  • Institutes for Behavior Resources, Inc., Baltimore, MD, USA.
  • Division of Sleep and Circadian Disorders, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Department of Anesthesia and Perioperative Medicine, Children's Hospital Boston, Boston, MA, USA.

ORCID-Profile: Monika Haack, Larissa C Engert, Michael R Goldstein, Jaime K Devine, Rammy Dang

Förderung

  • NCRR NIH HHS
  • NINDS NIH HHS
  • NHLBI NIH HHS
  • National Institutes of Health
  • National Institute of Neurological Disorders and Stroke
  • German Research Foundation
  • National Center for Research Resources

Zitieren

APA

Haack, M., Engert, L. C., Besedovsky, L., Goldstein, M. R., Devine, J. K., Dang, R., Olia, K., Molina, V., Bertisch, S. M., Sethna, N., & Simpson, N. (2023). Alterations of pain pathways by experimental sleep disturbances in humans: central pain-inhibitory, cyclooxygenase, and endocannabinoid pathways. SLEEP, 46(6). https://doi.org/10.1093/sleep/zsad061

Vancouver

Haack M, Engert LC, Besedovsky L, Goldstein MR, Devine JK, Dang R, et al. Alterations of pain pathways by experimental sleep disturbances in humans: central pain-inhibitory, cyclooxygenase, and endocannabinoid pathways. SLEEP. 2023;46(6). doi:10.1093/sleep/zsad061

BibTeX
@article{Haack2023,
  author = {Haack, Monika and Engert, Larissa C and Besedovsky, Luciana and Goldstein, Michael R and Devine, Jaime K and Dang, Rammy and Olia, Keeyon and Molina, Victoria and Bertisch, Suzanne M and Sethna, Navil and Simpson, Norah},
  title = {Alterations of pain pathways by experimental sleep disturbances in humans: central pain-inhibitory, cyclooxygenase, and endocannabinoid pathways},
  journal = {SLEEP},
  year = {2023},
  volume = {46},
  number = {6},
  doi = {10.1093/sleep/zsad061}
}
Kostenlos starten →